Thiazoles as 11 beta-HSD1 inhibitors

Details for Australian Patent Application No. 2007207055 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Kowalczyk, Agnieszka; Goodnow Jr., Robert Alan; Gillespie, Paul; Le, Kang; Zhang, Qiang

Agent Spruson & Ferguson

Pub. Number AU-B-2007207055

PCT Pub. Number WO2007/082808

Priority 60/759,676 18.01.06 US

Filing date 8 January 2007

Wipo publication date 26 July 2007

Acceptance publication date 2 June 2011

International Classifications

C07D 277/56 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

C07D 417/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

7 August 2008 PCT application entered the National Phase

  PCT publication WO2007/082808 Priority application(s): WO2007/082808

2 June 2011 Application Accepted

  Published as AU-B-2007207055

29 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007207064-Polyethylene composition for stretched tape products

2007207053-Arylisoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors